PROTECTing the kidneys in IgA nephropathy
- PMID: 37931627
- DOI: 10.1016/S0140-6736(23)02418-2
PROTECTing the kidneys in IgA nephropathy
Conflict of interest statement
HNR has provided consultation for Calliditas, Chinook, Novartis, and Omeros, and provided a conference lecture supported by Travere Therapeutics; serves on the steering committee of IgA studies for Calliditas and Chinook (a Novartis company); has attended advisory meetings for Otsuka, Pfizer, and Eledon; is a clinical trial site investigator for Calliditas, Omeros, and Alnylam; and directs the Louise Fast Foundation fellowship. SJB has provided consultation for Roche, Vera, BioCryst, BeiGene, Novartis, MorphoSys, Pfizer, and HIBio; has received investigator-initiated grant funding from Novartis and Alexion; and has worked on a data safety monitoring board for Eledon.
Comment on
- 
  
  Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
- Full Text Sources
- Miscellaneous
 
        